alpha-D-glucopyranose, 4,6-O-(phenylmethylene)- | 25152-90-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃二恶英
• 英文名称: alpha-D-glucopyranose, 4,6-O-(phenylmethylene)-
• 英文别名: 2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine-6,7,8-triol
• CAS: 25152-90-3
• 化学式: C₁₃H₁₆O₆
• 分子量: 268.266
• InChiKey: FOLRUCXBTYDAQK-UHFFFAOYSA-N

物化性质

• 熔点：
  188 °C
• 沸点：
  483.4±45.0 °C(Predicted)
• 密度：
  1.436±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  88.4
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 海关编码：
  2932999099

文献信息

• COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
  申请人：BROWN Joe Ernest

  公开号：US20160008388A1

  公开（公告）日：2016-01-14

  The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation. The immunotherapeutics of the present invention are particularly useful in the treatment of microbial infections and cellular proliferative disorders which are resistant to traditional methods of treatment such as antibiotics and chemotherapy

  本发明提供了新型免疫治疗组合物和方法，可用于治疗或预防微生物感染、免疫系统衰弱、细胞成为厌氧菌和细胞增殖性疾病，包括癌症。本发明所述的免疫治疗剂使用苯甲醛衍生物、前体和中间体单独或与其他治疗剂联合使用，以刺激免疫系统并抑制细胞增殖。本发明的免疫治疗剂在治疗微生物感染和细胞增殖性疾病方面特别有用，这些疾病对传统的治疗方法如抗生素和化疗具有抵抗力。
• NOVEL SUGAR-DERIVED GELLING AGENT
  申请人：Kyushu University

  公开号：EP2824157A1

  公开（公告）日：2015-01-14

  There is provided a novel gelator containing a sugar derivative. A gelator comprising a compound of Formula (1) or Formula (2): wherein each of R1 and R3 is independently a linear or branched alkyl group having a carbon atom number of 1 to 20, a cyclic C3-20 alkyl group, or a linear or branched alkenyl group having a carbon atom number of 2 to 20, n is 0 or an integer of 1 to 4, R2 is a hydrogen atom, a linear or branched alkyl group having a carbon atom number of 1 to 10, or an aryl group optionally having a substituent, and R4 and R5 are each a hydroxy group.

  本发明提供了一种含有糖衍生物的新型凝胶剂。凝胶剂包含式（1）或式（2）化合物： 其中R1和R3各自独立地为碳原子数为1至20的直链或支链烷基、环状C3-20烷基或碳原子数为2至20的直链或支链烯基，n为0或1至4的整数，R2为氢原子、碳原子数为1至10的直链或支链烷基或任选具有取代基的芳基，R4和R5各自为羟基。
• METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES
  申请人：Alexion Pharma International SÀRL

  公开号：EP2675278B1

  公开（公告）日：2016-02-17
• Compositions And Methods For Immunotherapy
  申请人：BROWN Joe Ernest

  公开号：US20090281047A1

  公开（公告）日：2009-11-12

  The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation. The immunotherapeutics of the present invention are particularly useful in the treatment of microbial infections and cellular proliferative disorders which are resistant to traditional methods of treatment such as antibiotics and chemotherapy
• Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies
  申请人：Brown Joe Ernest

  公开号：US20110311477A1

  公开（公告）日：2011-12-22

  The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anaerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation. The immunotherapeutics of the present invention are particularly useful in the treatment of microbial infections and cellular proliferative disorders which are resistant to traditional methods of treatment such as antibiotics and chemotherapy